Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Moleculin Biotech completes first cohort in Phase 1a trial of COVID-19 candidate » 08:39
06/16/22
06/16
08:39
06/16/22
08:39
MBRX

Moleculin Biotech

$1.40 /

+0.015 (+1.08%)

Moleculin Biotech…

Moleculin Biotech reported preliminary results from the first cohort of the xompany's first-in-human Phase 1a study of WP1122. This cohort consisted of 9 subjects dosed with 8 mg/kg or placebo in the dose escalation trial evaluating the safety and pharmacokinetics of WP1122 in healthy volunteers in the UK. Based on the overall results in Cohort 1, the company deemed the first cohort dose safe and well-tolerated and will open SAD Cohort 2 with a dose escalation to 16 mg/kg. The Phase 1a, first-in-human, randomized, double-blind, placebo-controlled, overlapping SAD and MAD is investigating the effects of WP1122 administered as an oral solution in healthy human volunteers. It is the first step in a planned investigation of WP1122 for the treatment of COVID-19. The company expects to enroll approximately 80 subjects in this trial. Moleculin is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.40 /

+0.015 (+1.08%)

MBRX Moleculin Biotech
$1.40 /

+0.015 (+1.08%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
Over a month ago
Hot Stocks
Moleculin Biotech begins dosing in Phase 1a clinical trial of COVID-19 candidate » 08:39
05/26/22
05/26
08:39
05/26/22
08:39
MBRX

Moleculin Biotech

$1.39 /

+0.075 (+5.70%)

Moleculin Biotech…

Moleculin Biotech commenced dosing in its first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19. The Phase 1a, first-in-human, overlapping Single and Multiple ascending dose will investigate the effects of WP1122 administered as an oral solution in healthy human volunteers in the U.K. This study in healthy volunteers will explore safety and PK, and subsequent antiviral clinical development will be in patients infected with SARS-CoV-2 to further evaluate safety and establish a favorable risk/benefit profile. Moleculin is also in the process of identifying additional countries where potential future Phase 2 COVID-19 clinical studies could occur.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.39 /

+0.075 (+5.70%)

MBRX Moleculin Biotech
$1.39 /

+0.075 (+5.70%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
Hot Stocks
Moleculin Biotech receives approval from UK MHRA for Phase 1a study of WP1122 » 08:37
05/10/22
05/10
08:37
05/10/22
08:37
MBRX

Moleculin Biotech

$1.30 /

-0.15 (-10.34%)

Moleculin Biotech…

Moleculin Biotech announced that it has received approval from the UK MHRA to proceed with a first-in-human Phase 1a study to evaluate the safety and pharmacokinetics of WP1122 in healthy volunteers for the treatment of COVID-19, or MB-301. The approval follows Moleculin's having submitted a protocol amendment allowing for a higher ratio of diluting excipients to drug substance to facilitate a faster and simpler mixing procedure before drug administration. WP1122, the Company's lead metabolism/glycosylation inhibitor, is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, currently being developed for inhibition of viral replication and disease manifestations in humans infected with SARS-CoV-2, the virus responsible for COVID-19. The mechanism of action of 2-DG includes both the inhibition of glycolysis and the disruption of glycosylation, two processes that are important to both viral activity and tumor development. WP1122 was developed as a 2-DG prodrug to provide a more favorable pharmacological profile, and was found to have greater potency than 2-DG alone in preclinical models where tumor cells require higher glycolytic activity than normal cells. WP1122 has also been shown to have a more potent antiviral effect than 2-DG against SARS-CoV-2 in MRC-5 cells in culture.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.30 /

-0.15 (-10.34%)

MBRX Moleculin Biotech
$1.30 /

-0.15 (-10.34%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
MBRX Moleculin Biotech
$1.30 /

-0.15 (-10.34%)

Hot Stocks
Moleculin Biotech's Phase 1/2 Annamycin study in AML allowed to proceed » 08:18
05/05/22
05/05
08:18
05/05/22
08:18
MBRX

Moleculin Biotech

$1.56 /

-0.055 (-3.42%)

Moleculin Biotech has…

Moleculin Biotech has received allowance from the Polish Department of Registration of Medicinal Products - URPL -, as well as the requisite Ethics Committee approval, to proceed with its Phase 1/2 clinical trial in Poland of Annamycin in combination with Cytarabine ) in the treatment of subjects with acute myeloid leukemia - AML - who are refractory to or relapsed after induction therapy. The Phase 1/2 L-ANN /ARA-C combination trial, an open label trial, builds on the safety and dosage data from the two successfully concluded single agent Annamycin AML Phase 1 trials in the U.S. and Europe and the preclinical data discussed below. The study is expected to commence patient enrollment in the first half of 2022. Annamycin is the company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin, as well as demonstrating the ability to avoid the multidrug resistance mechanisms that typically limit the efficacy of doxorubicin and other currently prescribed anthracyclines.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.56 /

-0.055 (-3.42%)

MBRX Moleculin Biotech
$1.56 /

-0.055 (-3.42%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
MBRX Moleculin Biotech
$1.56 /

-0.055 (-3.42%)

Hot Stocks
Moleculin Biotech receives IND clearance for Phase 1 study of glioma candidate » 08:55
04/21/22
04/21
08:55
04/21/22
08:55
MBRX

Moleculin Biotech

$1.92 /

+ (+0.00%)

Moleculin Biotech…

Moleculin Biotech announced that the FDA is allowing the company's Investigational New Drug application to study WP1066 for the treatment of recurrent malignant glioma. With this IND now cleared, Moleculin plans to evaluate strategic partnerships and collaborations to conduct a Phase 1 open label, single arm, dose escalation study of the safety, pharmacokinetics and efficacy of oral WP1066 in adult patients with recurrent malignant glioma. WP1066 is the company's flagship Immune/Transcription Modulator designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors. These transcription factors are widely sought targets that are believed to contribute to an increase in cell survival and proliferation. WP1066 is currently being evaluated for the treatment of pediatric brain tumors. The company has received Orphan Drug Designation for WP1066 for the treatment of brain tumors, as well as Rare Pediatric Disease designation for three other pediatric indications. Additionally, WP1066 + radiation is being evaluated, pre-clinically, in the treatment of Glioblastoma Multiforme. Glioma is a common type of tumor originating in the brain. About 33% of all brain tumors are gliomas.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.92 /

+ (+0.00%)

MBRX Moleculin Biotech
$1.92 /

+ (+0.00%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
MBRX Moleculin Biotech
$1.92 /

+ (+0.00%)

Hot Stocks
Moleculin Biotech announces corporate rebranding, launch of new website » 08:06
04/14/22
04/14
08:06
04/14/22
08:06
MBRX

Moleculin Biotech

$1.92 /

+0.07 (+3.78%)

Moleculin Biotech…

Moleculin Biotech announced the launch its new corporate branding and website www.moleculin.com. "As we drive clinical development across our broad portfolio of drug candidates, expand our growing body of clinical data and build value among all stakeholders, we believed it was an important step to refresh our corporate branding identity and website to align with the true potential and vision we have for Moleculin. We are wholeheartedly committed to potentially solving some of the toughest challenges and importantly, bringing better treatments to patients where there remains unmet medical need. The work completed and data demonstrated to-date bolsters our confidence as we believe we can successfully execute on a number of key clinical and regulatory milestones that will be instrumental in establishing a clear path to approval and commercialization of Annamycin. I am excited for this evolution of Moleculin and to take another step forward towards the future of this exciting company," commented Walter Klemp, Chairman and CEO of Moleculin.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.92 /

+0.07 (+3.78%)

MBRX Moleculin Biotech
$1.92 /

+0.07 (+3.78%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MBRX Moleculin Biotech
$1.92 /

+0.07 (+3.78%)

Hot Stocks
Moleculin Biotech to present preclinical annamycin data at AACR » 13:18
04/08/22
04/08
13:18
04/08/22
13:18
MBRX

Moleculin Biotech

$1.86 /

-0.01 (-0.53%)

Moleculin Biotech…

Moleculin Biotech announced that preclinical data of Annamycin tested in syngeneic models of metastatic colorectal cancer established in lungs or liver was accepted for poster presentation at the American Association for Cancer Research, or AACR, Annual Meeting 2022, being held April 8-13. Annamycin exhibited robust antitumor activity in both models. In the lung metastasis model, a dose-dependent delay in the tumor progression was visualized by both BLI and CT scan in the Annamycin treated group. The delay correlated with 272% extension of survival in the group receiving 6 mg/kg Annamycin and 234% for the animals dosed with Annamycin at 4 mg/kg. In the liver metastasis model, all vehicle-treated mice showed massive tumors in the liver and peritoneal cavity as monitored by BLI and MRI. In the vehicle group, 13/14 died or were euthanized by 35d. Yet, no tumors were detected by BLI or MRI in Annamycin treated mice as of 44d and 0/14 mice died. This indicates a highly significant extension of survival, the company said. "We continue to be encouraged by the growing body of robust preclinical and human clinical data demonstrated by Annamycin. The positive results seen in these preclinical models provide added confidence in the potential follow-on development opportunities we believe Annamycin holds. While metastatic colorectal cancer is not an immediate area of focus for us, this data set continues to provide valuable insight as we advance its clinical development for the treatment of highly resistant tumors," commented Walter Klemp, Chairman and CEO of Moleculin.

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.86 /

-0.01 (-0.53%)

MBRX Moleculin Biotech
$1.86 /

-0.01 (-0.53%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MBRX Moleculin Biotech
$1.86 /

-0.01 (-0.53%)

Over a quarter ago
Hot Stocks
Moleculin Biotech says cash sufficient to fund operations into 2024 » 07:07
03/25/22
03/25
07:07
03/25/22
07:07
MBRX

Moleculin Biotech

$1.76 /

+0.16 (+10.00%)

The company ended the…

The company ended the year with $70.9M of cash. The company believes that this cash is sufficient to meet its projected operating requirements, which include a forecasted increase over its current R&D rate of expenditures, into 2024. "Over the course of 2021, we have made significant progress across multiple fronts. As we look ahead, I believe we are well positioned for an exciting 2022 with a number of clinical and regulatory milestones expected throughout the year," commented Walter Klemp, Chairman and CEO of Moleculin. "Our Annamycin development programs in STS lung mets and AML continue to progress and we remain encouraged by the data seen to date. Additionally, with the necessary regulatory approvals received, we are advancing parallel development of WP1122 for the treatment of COVID-19 and GBM. With our growing body of encouraging clinical data and our strong financing position, we remain laser focused on executing our initiatives, driving value for all stakeholders, and importantly, addressing unmet needs for people with highly resistant tumors and viruses."

ShowHide Related Items >><<
MBRX Moleculin Biotech
$1.76 /

+0.16 (+10.00%)

MBRX Moleculin Biotech
$1.76 /

+0.16 (+10.00%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MBRX Moleculin Biotech
$1.76 /

+0.16 (+10.00%)

Conference/Events
Roth Capital to hold a conference » 04:55
03/16/22
03/16
04:55
03/16/22
04:55
ATNM

Actinium Pharmaceuticals

$4.66 /

+0.06 (+1.30%)

, AWKNF

Awakn Life Sciences

$1.32 /

+0.0183 (+1.41%)

, AXLA

Axcella Health

$1.94 /

-0.015 (-0.77%)

, CLNN

Clene

$2.44 /

-0.265 (-9.81%)

, COCP

Cocrystal Pharma

/

+

, FTRP

Field Trip Health

$1.02 /

-0.01 (-0.97%)

, FWBI

First Wave BioPharma

$1.07 /

+0.02 (+1.90%)

, FBIO

Fortress Biotech

$1.24 /

-0.01 (-0.80%)

, CMPS

Compass Pathways

$11.52 /

+0.31 (+2.77%)

, DARE

Dare Bioscience

$1.47 /

+0.02 (+1.38%)

, DCTH

Delcath Systems

$6.13 /

+0.01 (+0.16%)

, DHAC

Digital Health Acquisition

$9.97 /

+ (+0.00%)

, GLYC

GlycoMimetics

$1.03 /

+0.02 (+1.98%)

, KALV

KalVista

$14.49 /

+0.07 (+0.49%)

, KMPH

KemPharm

$5.11 /

+0.11 (+2.20%)

, LCI

Lannett

/

+

, LMAT

LeMaitre

$41.87 /

-0.08 (-0.19%)

, LGND

Ligand

$104.48 /

+4.18 (+4.17%)

, LUMO

Lumos Pharma

$8.86 /

-0.22 (-2.42%)

, MRKR

Marker Therapeutics

/

+

, PBLA

Panbela Therapeutics

$1.74 /

-0.04 (-2.25%)

, PIII

P3 Health Partners

$6.67 /

+0.18 (+2.77%)

, SKIN

Beauty Health

$15.60 /

-0.15 (-0.95%)

, SINT

Sintx Technologies

/

+

, MBRX

Moleculin Biotech

$1.28 /

+0.05 (+4.07%)

, MNPR

Monopar Therapeutics

$2.86 /

-0.07 (-2.39%)

, IRIX

Iridex

$4.09 /

-0.04 (-0.97%)

, IRMD

iRadimed

$46.67 /

+1.69 (+3.76%)

, INVO

INVO Bioscience

$2.20 /

-0.09 (-3.93%)

, INM

InMed Pharmaceuticals

/

+

, INDP

Indaptus Therapeutics

$3.17 /

-0.18 (-5.37%)

, ENSC

Ensysce Biosciences

$1.09 /

+0.035 (+3.32%)

, LIFE

aTyr Pharma

$4.74 /

+0.03 (+0.64%)

, ATAI

Atai Life Sciences

$4.94 /

-0.145 (-2.85%)

34th Annual ROTH…

34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link

ShowHide Related Items >><<
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

SINT Sintx Technologies
/

+

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

PBLA Panbela Therapeutics
$1.74 /

-0.04 (-2.25%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

LGND Ligand
$104.48 /

+4.18 (+4.17%)

LCI Lannett
/

+

KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

KALV KalVista
$14.49 /

+0.07 (+0.49%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

FWBI First Wave BioPharma
$1.07 /

+0.02 (+1.90%)

FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

CLNN Clene
$2.44 /

-0.265 (-9.81%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

ATNM Actinium Pharmaceuticals
$4.66 /

+0.06 (+1.30%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

ATNM Actinium Pharmaceuticals
$4.66 /

+0.06 (+1.30%)

09/15/21 Alliance Global Partners
Actinium price target lowered to $20 from $25 at Alliance Global Partners
08/03/21 H.C. Wainwright
Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences
$1.32 /

+0.0183 (+1.41%)

02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
CLNN Clene
$2.44 /

-0.265 (-9.81%)

11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
11/02/21 Benchmark
Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
05/20/21 Maxim
Clene initiated with a Buy at Maxim
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

02/17/22 Stifel
Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
11/22/21 H.C. Wainwright
Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
11/18/21 Stifel
Field Trip Health price target raised to C$11.50 from C$10 at Stifel
09/01/21 H.C. Wainwright
Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma
$1.07 /

+0.02 (+1.90%)

12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

10/26/21 Roth Capital
Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
06/17/21 B. Riley
Fortress Biotech price target lowered to $8 from $9 at B. Riley
04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

01/19/22 Brookline
Dare Bioscience assumed with a Buy at Brookline
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

12/10/21 H.C. Wainwright
Delcath Systems initiated with a Buy at H.C. Wainwright
06/08/21 Roth Capital
Delcath Systems data suggest approvability, says Roth Capital
04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition
$9.97 /

+ (+0.00%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

11/12/21
Fly Intel: Top five analyst upgrades
11/12/21 Jefferies
GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
11/12/21 Jefferies
GlycoMimetics upgraded to Buy from Hold at Jefferies
09/27/21 Roth Capital
GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
KALV KalVista
$14.49 /

+0.07 (+0.49%)

11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
08/23/21 Roth Capital
KalVista could take 'substantial' share of HAE market, says Roth Capital
04/20/21 Roth Capital
KalVista selloff seems overdone after clinical hold, says Roth Capital
KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

01/31/22 H.C. Wainwright
KemPharm upgraded to Buy from Neutral at H.C. Wainwright
05/26/21 Roth Capital
Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
LCI Lannett
/

+

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

02/25/22 Barrington
LeMaitre price target lowered to $54 from $62 at Barrington
09/16/21
Fly Intel: Top five analyst initiations
09/16/21 Jefferies
Jefferies starts LeMaitre at Buy on ArteGraft upside potential
09/16/21 Jefferies
LeMaitre initiated with a Buy at Jefferies
LGND Ligand
$104.48 /

+4.18 (+4.17%)

02/22/22 Benchmark
Ligand price target lowered to $130 from $180 at Benchmark
02/18/22 Barclays
Ligand price target lowered to $165 from $185 at Barclays
09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
LUMO Lumos Pharma
$8.86 /

-0.22 (-2.42%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
MRKR Marker Therapeutics
/

+

02/17/22 Roth Capital
Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
02/17/22 Piper Sandler
Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics
$1.74 /

-0.04 (-2.25%)

02/23/22 Craig-Hallum
Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

03/14/22 Benchmark
Beauty Health price target raised to $23 from $18 at Benchmark
03/11/22 JPMorgan
Beauty Health initiated with an Overweight at JPMorgan
01/07/22 William Blair
William Blair starts Beauty Health with Outperform, sees 20%-plus growth
01/07/22 William Blair
Beauty Health initiated with an Outperform at William Blair
SINT Sintx Technologies
/

+

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
IRIX Iridex
$4.09 /

-0.04 (-0.97%)

03/02/22 Stifel
Iridex transferred with Buy rating at Stifel
IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

11/02/21 Roth Capital
iRadimed price target raised to $42 from $36 at Roth Capital
INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

01/19/22 Maxim
INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals
/

+

11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

11/30/21 Lake Street
Ensysce Biosciences initiated with a Buy at Lake Street
LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

11/11/21 Roth Capital
aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
10/12/21 RBC Capital
aTyr Pharma initiated with an Outperform at RBC Capital
09/21/21 Piper Sandler
aTyr Pharma initiated with an Overweight at Piper Sandler
09/14/21 Oppenheimer
aTyr Pharma price target raised to $20 from $14 at Oppenheimer
ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

PIII P3 Health Partners
$6.67 /

+0.18 (+2.77%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.86 /

-0.07 (-2.39%)

MBRX Moleculin Biotech
$1.28 /

+0.05 (+4.07%)

LUMO Lumos Pharma
$8.86 /

-0.22 (-2.42%)

LMAT LeMaitre
$41.87 /

-0.08 (-0.19%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

LGND Ligand
$104.48 /

+4.18 (+4.17%)

LCI Lannett
/

+

KALV KalVista
$14.49 /

+0.07 (+0.49%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

IRIX Iridex
$4.09 /

-0.04 (-0.97%)

INVO INVO Bioscience
$2.20 /

-0.09 (-3.93%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.17 /

-0.18 (-5.37%)

GLYC GlycoMimetics
$1.03 /

+0.02 (+1.98%)

FTRP Field Trip Health
$1.02 /

-0.01 (-0.97%)

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

CLNN Clene
$2.44 /

-0.265 (-9.81%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

  • 16
    Sep
  • 14
    Jul
  • 18
    Jun
  • 30
    Apr
AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

IRMD iRadimed
$46.67 /

+1.69 (+3.76%)

IRIX Iridex
$4.09 /

-0.04 (-0.97%)

INM InMed Pharmaceuticals
/

+

FBIO Fortress Biotech
$1.24 /

-0.01 (-0.80%)

DHAC Digital Health Acquisition
$9.97 /

+ (+0.00%)

DCTH Delcath Systems
$6.13 /

+0.01 (+0.16%)

DARE Dare Bioscience
$1.47 /

+0.02 (+1.38%)

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

AXLA Axcella Health
$1.94 /

-0.015 (-0.77%)

AWKNF Awakn Life Sciences
$1.32 /

+0.0183 (+1.41%)

SKIN Beauty Health
$15.60 /

-0.15 (-0.95%)

LIFE aTyr Pharma
$4.74 /

+0.03 (+0.64%)

KMPH KemPharm
$5.11 /

+0.11 (+2.20%)

ENSC Ensysce Biosciences
$1.09 /

+0.035 (+3.32%)

CMPS Compass Pathways
$11.52 /

+0.31 (+2.77%)

ATAI Atai Life Sciences
$4.94 /

-0.145 (-2.85%)

Conference/Events
Roth Capital to hold a conference » 04:55
03/15/22
03/15
04:55
03/15/22
04:55
ATNM

Actinium Pharmaceuticals

$4.60 /

-0.2 (-4.17%)

, AWKNF

Awakn Life Sciences

$1.30 /

+0.0017 (+0.13%)

, AXLA

Axcella Health

$2.01 /

-0.035 (-1.71%)

, CLNN

Clene

$2.70 /

-0.11 (-3.91%)

, COCP

Cocrystal Pharma

/

+

, FTRP

Field Trip Health

$1.03 /

-0.02 (-1.90%)

, FWBI

First Wave BioPharma

$1.06 /

-0.07 (-6.19%)

, FBIO

Fortress Biotech

$1.24 /

-0.11 (-8.15%)

, CMPS

Compass Pathways

$11.17 /

-0.97 (-7.99%)

, DARE

Dare Bioscience

$1.45 /

-0.08 (-5.25%)

, DCTH

Delcath Systems

$6.12 /

+0.2 (+3.38%)

, DHAC

Digital Health Acquisition

$9.97 /

+0.01 (+0.10%)

, GLYC

GlycoMimetics

$1.01 /

-0.09 (-8.18%)

, KALV

KalVista

$14.39 /

-1.06 (-6.86%)

, KMPH

KemPharm

$5.00 /

-0.255 (-4.86%)

, LCI

Lannett

/

+

, LMAT

LeMaitre

$41.93 /

-0.56 (-1.32%)

, LGND

Ligand

$101.10 /

-3.44 (-3.29%)

, LUMO

Lumos Pharma

$8.86 /

-0.16 (-1.77%)

, MRKR

Marker Therapeutics

/

+

, PBLA

Panbela Therapeutics

$1.77 /

-0.04 (-2.21%)

, PIII

P3 Health Partners

$6.47 /

-0.385 (-5.62%)

, SKIN

Beauty Health

$15.75 /

-1.915 (-10.84%)

, SINT

Sintx Technologies

/

+

, MBRX

Moleculin Biotech

$1.23 /

-0.08 (-6.11%)

, MNPR

Monopar Therapeutics

$2.87 /

-0.07 (-2.38%)

, IRIX

Iridex

$4.10 /

+ (+0.00%)

, IRMD

iRadimed

$44.98 /

-1.645 (-3.53%)

, INVO

INVO Bioscience

$2.29 /

+0.02 (+0.88%)

, INM

InMed Pharmaceuticals

/

+

, INDP

Indaptus Therapeutics

$3.30 /

-0.305 (-8.46%)

, ENSC

Ensysce Biosciences

$1.06 /

-0.045 (-4.09%)

, LIFE

aTyr Pharma

$4.75 /

-0.5 (-9.52%)

, ATAI

Atai Life Sciences

$5.08 /

-0.145 (-2.78%)

34th Annual ROTH…

34th Annual ROTH Conference to be held in Dana Point, CA on March 13-16. Webcast Link

ShowHide Related Items >><<
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

SINT Sintx Technologies
/

+

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

PBLA Panbela Therapeutics
$1.77 /

-0.04 (-2.21%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

LGND Ligand
$101.10 /

-3.44 (-3.29%)

LCI Lannett
/

+

KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

KALV KalVista
$14.39 /

-1.06 (-6.86%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

FWBI First Wave BioPharma
$1.06 /

-0.07 (-6.19%)

FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

CLNN Clene
$2.70 /

-0.11 (-3.91%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

ATNM Actinium Pharmaceuticals
$4.60 /

-0.2 (-4.17%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

ATNM Actinium Pharmaceuticals
$4.60 /

-0.2 (-4.17%)

09/15/21 Alliance Global Partners
Actinium price target lowered to $20 from $25 at Alliance Global Partners
08/03/21 H.C. Wainwright
Actinium Pharmaceuticals price target lowered to $45 from $57 at H.C. Wainwright
04/06/21 William Blair
Actinium's Q4 net loss roughly in line with projected loss, says William Blair
AWKNF Awakn Life Sciences
$1.30 /

+0.0017 (+0.13%)

02/01/22 H.C. Wainwright
Awakn Life Sciences initiated with a Buy at H.C. Wainwright
AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

10/12/21 Noble Capital
Axcella Health initiated with an Outperform at Noble Capital
09/22/21 Goldman Sachs
Axcella Health downgraded to Neutral from Buy at Goldman Sachs
07/30/21 JPMorgan
Axcella downgraded to Underweight on lack of catalysts at JPMorgan
07/30/21 JPMorgan
Axcella Health downgraded to Underweight from Neutral at JPMorgan
CLNN Clene
$2.70 /

-0.11 (-3.91%)

11/03/21 Cantor Fitzgerald
Clene price target lowered to $15 from $24 at Cantor Fitzgerald
11/02/21 Roth Capital
Roth reiterates Buy on Clene after unblinded analysis of CNM-Au8 in ALS trial
11/02/21 Benchmark
Benchmark would be buyer of Clene on weakness after RESCUE-ALS data
05/20/21 Maxim
Clene initiated with a Buy at Maxim
COCP Cocrystal Pharma
/

+

06/15/21 H.C. Wainwright
Cocrystal Pharma price target lowered to $4 from $4.50 at H.C. Wainwright
FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

02/17/22 Stifel
Field Trip Health price target lowered to C$10.50 from C$11.50 at Stifel
11/22/21 H.C. Wainwright
Field Trip Health price target raised to $25 from $20 at H.C. Wainwright
11/18/21 Stifel
Field Trip Health price target raised to C$11.50 from C$10 at Stifel
09/01/21 H.C. Wainwright
Field Trip Health initiated with a Buy at H.C. Wainwright
FWBI First Wave BioPharma
$1.06 /

-0.07 (-6.19%)

12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
12/07/21 Maxim
First Wave BioPharma downgraded to Hold from Buy at Maxim
FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

10/26/21 Roth Capital
Avenue Therapeutics FDA panel positive for Fortress Biotech, says Roth Capital
09/29/21 H.C. Wainwright
H.C. Wainwright says Astra deal for Caelum to yield 'nice check' for Fortress
06/17/21 B. Riley
Fortress Biotech price target lowered to $8 from $9 at B. Riley
04/14/21 B. Riley
Fortress Biotech weakness yesterday a buying opportunity, says B. Riley
CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

02/28/22 Canaccord
Compass Pathways price target lowered to $78 from $80 at Canaccord
11/11/21 Roth Capital
Atai Life Sciences initiated with a Buy at Roth Capital
11/09/21 Citi
Citi says Compass Pathways selloff overdone, ups price target to $70
11/09/21 Cantor Fitzgerald
Compass Pathways price target raised to $82 from $71 at Cantor Fitzgerald
DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

01/19/22 Brookline
Dare Bioscience assumed with a Buy at Brookline
07/12/21 Roth Capital
Roth adds more 'SMID-cap' names to second half top picks
07/12/21 Roth Capital
Dare Bioscience NIH agreement should offset costs, says Roth Capital
07/07/21 Roth Capital
Dare Bioscience grant reflects large market need, says Roth Capital
DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

12/10/21 H.C. Wainwright
Delcath Systems initiated with a Buy at H.C. Wainwright
06/08/21 Roth Capital
Delcath Systems data suggest approvability, says Roth Capital
04/06/21 Roth Capital
Delcath Systems price target raised to $25 from $20 at Roth Capital
DHAC Digital Health Acquisition
$9.97 /

+0.01 (+0.10%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

11/12/21
Fly Intel: Top five analyst upgrades
11/12/21 Jefferies
GlycoMimetics upgraded to Buy at Jefferies as AML data looked 'very promising'
11/12/21 Jefferies
GlycoMimetics upgraded to Buy from Hold at Jefferies
09/27/21 Roth Capital
GlycoMimetics' Upro swiftly advancing in China, says Roth Capital
KALV KalVista
$14.39 /

-1.06 (-6.86%)

11/10/21 Roth Capital
KalVista FDA meeting feedback 'quite positive,' says Roth Capital
08/23/21 Roth Capital
KalVista could take 'substantial' share of HAE market, says Roth Capital
04/20/21 Roth Capital
KalVista selloff seems overdone after clinical hold, says Roth Capital
KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

01/31/22 H.C. Wainwright
KemPharm upgraded to Buy from Neutral at H.C. Wainwright
05/26/21 Roth Capital
Orange Book lists 6 KemPharm SDX patents, confirms as an NCE, says Roth Capital
LCI Lannett
/

+

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

02/25/22 Barrington
LeMaitre price target lowered to $54 from $62 at Barrington
09/16/21
Fly Intel: Top five analyst initiations
09/16/21 Jefferies
Jefferies starts LeMaitre at Buy on ArteGraft upside potential
09/16/21 Jefferies
LeMaitre initiated with a Buy at Jefferies
LGND Ligand
$101.10 /

-3.44 (-3.29%)

02/22/22 Benchmark
Ligand price target lowered to $130 from $180 at Benchmark
02/18/22 Barclays
Ligand price target lowered to $165 from $185 at Barclays
09/22/21 Barclays
Ligand price target raised to $180 from $174 at Barclays
08/25/21 H.C. Wainwright
Ligand gets royalty on sales of Merck's Vaxneuvance, says H.C. Wainwright
LUMO Lumos Pharma
$8.86 /

-0.16 (-1.77%)

08/05/21 Piper Sandler
Lumos shares trading below cash, says Piper Sandler
07/22/21 Roth Capital
Lumos Pharma price target lowered to $35 from $51 at Roth Capital
07/21/21 Piper Sandler
Piper says Lumos Pharma's OraGrowtH210 trial delay 'not a problem'
07/21/21 H.C. Wainwright
Lumos Pharma price target lowered to $27 from $34 at H.C. Wainwright
MRKR Marker Therapeutics
/

+

02/17/22 Roth Capital
Marker Therapeutics downgraded to Neutral from Buy at Roth Capital
02/17/22 Piper Sandler
Marker Therapeutics price target lowered to $4 from $5.50 at Piper Sandler
03/25/21 Piper Sandler
Marker Therapeutics initiated with an Overweight at Piper Sandler
03/19/21
Fly Intel: Top five analyst initiations
PBLA Panbela Therapeutics
$1.77 /

-0.04 (-2.21%)

02/23/22 Craig-Hallum
Panbela Therapeutics price target raised to $13 from $9 at Craig-Hallum
06/28/21 Roth Capital
Panbela Therapeutics initiated with a Buy at Roth Capital
PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

01/04/22 William Blair
P3 Health Partners initiated with an Outperform at William Blair
12/28/21 Lake Street
Lake Street names 18 small cap best ideas for 2022
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

03/14/22 Benchmark
Beauty Health price target raised to $23 from $18 at Benchmark
03/11/22 JPMorgan
Beauty Health initiated with an Overweight at JPMorgan
01/07/22 William Blair
William Blair starts Beauty Health with Outperform, sees 20%-plus growth
01/07/22 William Blair
Beauty Health initiated with an Outperform at William Blair
SINT Sintx Technologies
/

+

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

12/01/21 Roth Capital
Roth Capital bullish on Moleculin as FDA clears WP1122 for Phase 1 GBM trial
07/13/21 Roth Capital
Moleculin to extend dose escalation in Phase 1/2 trial, says Roth Capital
04/14/21 Roth Capital
Moleculin gets 4th RPD for WP1066, four potential PRVs, says Roth Capital
MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

11/01/21 H.C. Wainwright
Monopar Therapeutics initiated with a Buy at H.C. Wainwright
10/19/21 Roth Capital
Roth Capital bullish on Monopar Therapeutics after competitor trial fails
IRIX Iridex
$4.10 /

+ (+0.00%)

03/02/22 Stifel
Iridex transferred with Buy rating at Stifel
IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

11/02/21 Roth Capital
iRadimed price target raised to $42 from $36 at Roth Capital
INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

01/19/22 Maxim
INVO Bioscience initiated with a Buy at Maxim
INM InMed Pharmaceuticals
/

+

11/29/21 H.C. Wainwright
InMed Pharmaceuticals initiated with a Buy at H.C. Wainwright
INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

01/31/22 H.C. Wainwright
Indaptus Therapeutics assumed with a Buy at H.C. Wainwright
10/19/21
Fly Intel: Top five analyst upgrades
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
10/19/21 Maxim
Indaptus Therapeutics upgraded to Buy from Hold at Maxim
ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

11/30/21 Lake Street
Ensysce Biosciences initiated with a Buy at Lake Street
LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

11/11/21 Roth Capital
aTyr Pharma 2022 catalysts 'should be on your radar,' says Roth Capital
10/12/21 RBC Capital
aTyr Pharma initiated with an Outperform at RBC Capital
09/21/21 Piper Sandler
aTyr Pharma initiated with an Overweight at Piper Sandler
09/14/21 Oppenheimer
aTyr Pharma price target raised to $20 from $14 at Oppenheimer
ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

11/30/21
Fly Intel: Top five analyst initiations
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/30/21 Maxim
Atai Life Sciences initiated with a Buy at Maxim
11/22/21 Canaccord
Atai Life Sciences weakness a buying opportunity, says Canaccord
SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

PIII P3 Health Partners
$6.47 /

-0.385 (-5.62%)

MRKR Marker Therapeutics
/

+

MNPR Monopar Therapeutics
$2.87 /

-0.07 (-2.38%)

MBRX Moleculin Biotech
$1.23 /

-0.08 (-6.11%)

LUMO Lumos Pharma
$8.86 /

-0.16 (-1.77%)

LMAT LeMaitre
$41.93 /

-0.56 (-1.32%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

LGND Ligand
$101.10 /

-3.44 (-3.29%)

LCI Lannett
/

+

KALV KalVista
$14.39 /

-1.06 (-6.86%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

IRIX Iridex
$4.10 /

+ (+0.00%)

INVO INVO Bioscience
$2.29 /

+0.02 (+0.88%)

INM InMed Pharmaceuticals
/

+

INDP Indaptus Therapeutics
$3.30 /

-0.305 (-8.46%)

GLYC GlycoMimetics
$1.01 /

-0.09 (-8.18%)

FTRP Field Trip Health
$1.03 /

-0.02 (-1.90%)

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

COCP Cocrystal Pharma
/

+

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

CLNN Clene
$2.70 /

-0.11 (-3.91%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

  • 16
    Sep
  • 14
    Jul
  • 18
    Jun
  • 30
    Apr
AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

IRMD iRadimed
$44.98 /

-1.645 (-3.53%)

IRIX Iridex
$4.10 /

+ (+0.00%)

INM InMed Pharmaceuticals
/

+

FBIO Fortress Biotech
$1.24 /

-0.11 (-8.15%)

DHAC Digital Health Acquisition
$9.97 /

+0.01 (+0.10%)

DCTH Delcath Systems
$6.12 /

+0.2 (+3.38%)

DARE Dare Bioscience
$1.45 /

-0.08 (-5.25%)

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

AXLA Axcella Health
$2.01 /

-0.035 (-1.71%)

AWKNF Awakn Life Sciences
$1.30 /

+0.0017 (+0.13%)

SKIN Beauty Health
$15.75 /

-1.915 (-10.84%)

LIFE aTyr Pharma
$4.75 /

-0.5 (-9.52%)

KMPH KemPharm
$5.00 /

-0.255 (-4.86%)

ENSC Ensysce Biosciences
$1.06 /

-0.045 (-4.09%)

CMPS Compass Pathways
$11.17 /

-0.97 (-7.99%)

ATAI Atai Life Sciences
$5.08 /

-0.145 (-2.78%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.